*One Stock Before the Bell*
*Vertex Pharmaceuticals Inc (NASDAQ: VRTX)*
$300.94 (+4.21% YTD)
Vertex develops and markets drugs that treat rare genetic diseases such as cystic fibrosis (CF). Growth will be driven by cash cow *Trikafta*, which makes up 86.13% of revenue, and whose patent only expires in 2037. VRTX has the *competitive advantage of being the only seller of CFTR modulators on the market*, with CFTR being vital for the treatment of CF.
*Q3 EPS and revenue* grew by 12.64% YoY and 17.65% respectively. Growth prospects in other treatments areas look promising, with *Exa-Cell, a gene-editing treatment for sickle cell disease developed in collaboration CRISPR Therapeutics, on track to gain regulatory approval in the UK and Europe later this year*. VRTX's pipeline also features *5 potential launches over the next 5 years.* The stock looks undervalued at a *blended forward P/E ratio of 19.0x*, a *32% discount* to its 5Y average P/E.
*Vertex Pharmaceuticals Inc (NASDAQ: VRTX)*
$300.94 (+4.21% YTD)
Vertex develops and markets drugs that treat rare genetic diseases such as cystic fibrosis (CF). Growth will be driven by cash cow *Trikafta*, which makes up 86.13% of revenue, and whose patent only expires in 2037. VRTX has the *competitive advantage of being the only seller of CFTR modulators on the market*, with CFTR being vital for the treatment of CF.
*Q3 EPS and revenue* grew by 12.64% YoY and 17.65% respectively. Growth prospects in other treatments areas look promising, with *Exa-Cell, a gene-editing treatment for sickle cell disease developed in collaboration CRISPR Therapeutics, on track to gain regulatory approval in the UK and Europe later this year*. VRTX's pipeline also features *5 potential launches over the next 5 years.* The stock looks undervalued at a *blended forward P/E ratio of 19.0x*, a *32% discount* to its 5Y average P/E.
选择“Disable on www.wenxuecity.com”
选择“don't run on pages on this domain”
